When it comes to cancer, late stage diagnosis is correlated with less effective treatment and a poor prognosis. And while cancer research has mainly focused finding cures, there is an unmet need for diagnostic tools that allow…Continue
Added by Editorial Team on August 9, 2016 at 2:00pm — No Comments
Alfred G. Knudson, Jr., MD, PhD (photo), a pioneering cancer researcher who is internationally recognized for his groundbreaking “two-hit” hypothesis, which helped provide the basis for our current understanding of the genetic origins of cancer passed away on July 10, 2016 at 93 years of age.
“The [...] cancer research world as a whole has lost a true visionary with the passing of Knudson. He proposed the two-hit hypothesis many years before the molecular technologies needed…Continue
Added by Editorial Team on July 12, 2016 at 10:00am — No Comments
Following a positive opinion from the Committee for Medicinal Products for Human Use issued on May 26, 2016, the European Commission (EC) has extended the current conditional marketing authorization of brentuximab vedotin (Adcetris®/Seattle Genetics/Takeda Oncology). The drug is now…Continue
Added by Editorial Team on July 11, 2016 at 11:30am — No Comments
As a cardiologist, it is tempting for me to use this platform to talk about heart disease. Instead I have decided to push myself beyond that, connecting to my cardiology…Continue
Added by Editorial Team on July 6, 2016 at 9:30pm — No Comments
While immune therapy has proven effective in treating certain types of cancer, especially lung cancer and melanoma, tumors of the pancreas remain among the most difficult to treat and, so far, are impervious to immune-based therapies.
Now, for the first time, a new study in mice has shown that immunotherapy against pancreatic cancer can be effective when given in conjunction with drugs that break up the fibrous tissue in these tumors.
The study, from Washington University…Continue
Added by Editorial Team on July 4, 2016 at 11:00am — No Comments
A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented at the European Society for Medical Oncology’s 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. 
Xilonix™ (XBiotech) is the first…Continue
Added by Editorial Team on July 2, 2016 at 11:00am — No Comments
Improved cancer detection and treatment efforts, combined with demographic trends, are creating larger numbers of older cancer survivors who are likely to have other health conditions that impact care and well-being. This is the conclusion of new research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American…Continue
Added by Editorial Team on July 1, 2016 at 5:00pm — No Comments
This week Targovax, a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announced that the first patient has been dosed in a phase Ib/II clinical trial evaluating ONCOS-102 for the treatment of malignant pleural mesothelioma (MPM), a rare type of cancer in the lining of the lung, in combination with pemetrexed and cisplatin.
ONCOS - 102 is a virus-based immunotherapy platform based on engineered…Continue
Added by Editorial Team on June 30, 2016 at 4:30pm — No Comments
Dosing of the first patient in a Phase I clinical trial of BGB-3111, a Bruton’s tyrosine kinase (BTK) inhibitor, in combination with BGB-A317, a PD-1 antibody, for the treatment of various B-cell malignancies was initiated earlier this week. This combination study of two internal drug candidates being developed by BeiGene, a clinical-stage biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer, follows an ongoing study of…Continue
Added by Editorial Team on June 29, 2016 at 8:30pm — No Comments
Women with a history of severe cervical intraepithelial neoplasia, a precancerous condition of the cervix that arises from infection with the human papillomavirus (HPV), had a long-term increased risk of developing anal, vulvar, and vaginal cancer. This is the conclusion of a study, funded by the Unit of Virus, Lifestyle, and Genes at the Danish Cancer Society Research Center, published in Cancer Epidemiology,…Continue
Added by Editorial Team on June 29, 2016 at 6:00pm — No Comments
Following cancer prevention guidelines on diet and physical activity consistently reduced overall cancer incidence and mortality, as well as reducing risk of breast, endometrial, and colorectal cancers. Conclusions of the study, funded by a National Cancer Institute Cancer Center support grant, were published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the …Continue
Added by Editorial Team on June 23, 2016 at 6:30pm — No Comments
Researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, Princess Margaret Cancer Center, the University of Toronto, Harvard Medical School and Oxford University have identified a new signaling pathway that helps cancer cells cope with the lack of oxygen found inside tumors. These are the results of a study published in Nature Cell Biology on June 20, 2016.
Added by Editorial Team on June 20, 2016 at 11:00am — No Comments
Quality of life—it’s a term that gets thrown around a lot when people are sick. The phrase refers to how well you can live the life you want and how happy you are during it. For patients with life-threatening conditions like colorectal cancer, it’s common to wonder, “What will I be like after my chemotherapy or radiation are over?” It’s a question that can be hard to answer and the truth is that life after cancer can look very different from patient to patient. How your life changes will…Continue
Added by Editorial Team on June 16, 2016 at 8:00am — No Comments
Metastatic ovarian cancer patients treated with chemotherapy prior to surgery had altered immune cells in their tumors, and specific alterations identified suggest that immunotherapy given after chemotherapy may help in preventing the cancer from coming back.This is a conclusion of a study, funded by Swiss Cancer League, the European Research Council, Cancer Research U.K., and Barts and the London Charity, and published in…Continue
Added by Editorial Team on June 15, 2016 at 8:00pm — No Comments
A newly devised tumor-specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery. That is an observation from a stud, study supported by On Target Laboratories, reported in Clinical Cancer…Continue
Added by Editorial Team on June 15, 2016 at 7:30pm — No Comments
Examining databases of proteins’ 3-D shapes, scientists at Washington University School of Medicine in St. Louis have identified more than 850 DNA mutations that appear to be linked to cancer. The information may expand the number of cancer patients who can benefit from existing drugs. 
The study, published June 13 in Nature Genetics, detailed a list of the…Continue
Added by Editorial Team on June 13, 2016 at 12:00pm — No Comments
A pilot study revealed large differences in median retail prices for 23 cancer drugs in seven different countries, with the highest retail prices identified in the United States and the lowest in India and South Africa. Notably, after monthly drug price is expressed as a percentage of domestic product per capita at purchasing power parity (GDPcapPPP), cancer drugs appear to be less affordable in low-income countries, despite the lower retail prices. The study was featured…Continue
Added by Editorial Team on June 7, 2016 at 2:00pm — No Comments
Early findings from a first-in-human clinical trial showed that the antibody drug conjugate or ADC rovalpituzumab tesirine (Rova-T; SC16LD6.5) shows promising efficacy against recurrent small cell lung cancer (SCLC). The treatment, which combines a novel anti-DLL3 antibody with a powerful…Continue
Added by Editorial Team on June 6, 2016 at 11:30pm — No Comments
New preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine being developed by Nectar Therapeutics is currently being evaluated in cancer patients with solid tumors in a Phase I/II clinical trial being conducted at MD Anderson Cancer Center and Yale Cancer Center.
Added by Editorial Team on June 6, 2016 at 8:30pm — No Comments
First-time clinical data for ASG-15ME and ASG-22ME (Enfortumab vedotin) were presented today at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016 in Chicago, IL.
ASG-15ME and ASG-22ME are investigational…Continue
Added by Editorial Team on June 6, 2016 at 12:00pm — No Comments